Publications by authors named "Ali Fuat Gurbuz"
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with a poor prognosis. Identifying reliable prognostic factors is crucial for risk stratification and optimizing treatment strategies. This study aimed to evaluate the impact of clinicopathologic factors and systemic inflammatory markers on survival outcomes in patients with MPM.
View Article and Find Full Text PDFArticle Synopsis
- Ado-trastuzumab emtansine (T-DM1) is a targeted therapy for HER2-positive breast cancer, commonly causing side effects like fatigue, diarrhea, and thrombocytopenia.
- A 54-year-old woman treated for metastatic breast cancer developed drug-induced lupus after 18 months on T-DM1, which improved upon stopping the drug and starting hydroxychloroquine.
- This case is notable as it documents the first reported instance of drug-induced lupus specifically linked to T-DM1 therapy.
Introduction: Lorlatinib is a potent third-generation anaplastic lymphoma kinase/c-ros oncogene 1 (ALK)/ROS1 oral tyrosine kinase inhibitor that has broad coverage of acquired resistance mutations and is currently indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK-positive.
Case Report: In this case, we aimed to present the safety and effectiveness of lorlatinib use in a patient diagnosed with ALK-positive metastatic NSCLC who underwent hemodialysis 3 days a week.
Management & Outcome: A 76-year-old female patient has been undergoing regular hemodialysis for about 2 years.
Article Synopsis
- Bloom syndrome (BS) is a rare genetic disorder caused by mutations in the BLM gene, leading to difficulties in DNA repair and increased sensitivity to chemotherapy and radiation, complicating cancer treatment.
- A case study details a 30-year-old BS patient with early-stage triple-negative breast cancer who underwent an aggressive chemotherapy regimen and radiotherapy but developed severe complications, including myelodysplastic syndrome and ultimately sepsis, resulting in her death at age 33.
- The conclusion emphasizes the need for specialized multidisciplinary care in BS patients with cancer due to the lack of clinical trial data and the importance of carefully balancing treatment risks with potential benefits.
Hypoxia-inducible factor-1α and ischemia-modified albumin levels in intensive care COVID-19 Patients.
Horm Mol Biol Clin Investig
December 2022
Objectives: In this study, it was aimed to evaluate the hypoxia-inducible factor-1α (HIF-1α) and ischemia-modified albumin (IMA) levels of patients diagnosed with COVID-19 in the intensive care unit (ICU) and healthy controls. To our knowledge, this is the first study investigate HIF-1α and IMA levels in COVID-19 patients in ICUs and comparing them with a healthy control group. For this reason, our study is original and will contribute to the literature.
View Article and Find Full Text PDF